Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Moberg Pharma Q1: In the midst of the high season - Redeye

Analys | Redeye

•

14 May 11:16

Moberg Pharma Q1: In the midst of the high season - Redeye

Acarix Q1: Strong foundation for eventual ramp-up - Redeye

Redeye provides an update on Acarix following its Q1 report, which showed continued growth in revenu...

Starbreeze: Benefit from independence - Redeye

Cantargia Q1 2025: Approaching Crucial TRIFOUR Readout - Redeye

Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results...

Cantargia

Analys | Analyst Group

•

14 May 10:29

AcuCort: Starka triggers i närtid - Analyst Group

Enviro Q1 2025: No drama - Redeye

Redeye comments on Enviro’s Q1 report, which presented no real surprises.

Scandinavian Enviro

Analys | Analyst Group

•

14 May 09:56

Analyst Group Comment on Irisity’s Q1 Report for 2025

Irisity

Analys | ABG Sundal Collier

•

14 May 09:55

Gentoo Media: Big Q1 miss as Brazil weighs heavy - ABG

Q1 sales 20% below cons, partly driven by Brazil impact Adj.

Navigo Invest Q1 2025: Slight miss but decent performance and prospects for 2025e - Redeye

SenzaGen: Q1 Initial take – Sales a bit lower than estimated - Redeye

Redeye provides an initial take following the release of SenzaGen’s Q1 2025 report.

Gentoo Media Q1 2025: Weak results due to larger than expected headwind in Brazil - Redeye

Gentoo Media

Analys | ABG Sundal Collier

•

14 May 08:35

Eolus Vind: Pome 75% completed, 25% remaining - ABG

Q1 EBIT SEK 164m (vs. ABSCe 253m) Pome sales biggest contributor, Stor-Skälsjön completed Pome 75% c...

Better Collective Q1 2025E preview: Brazil in focus - Redeye

Surgical Science Q1 2025: Solid beat versus soft comparables, lowered 2026e financial targets - Redeye

Redeye provides its initial take on Surgical Science’s Q1 2025 report, which mostly beat our estimat...

Indutrade: An overview of the company - Redeye

CoinShares: Solid profitability overshadowed by end-of-period AUM - Redeye

Redeye updates its estimates and fair value range following CoinShares' Q1 2025 report.

Nekkar: Q1 Review – Short-Term Softness, Fundamentals Intact - Redeye

Smart Eye: Next station – Positive EBITDA - Redeye

Redeye revises its estimates for Smart Eye following interesting industry developments.

Relais: Focus on growth initiatives - Nordea

Relais Group

Analys | ABG Sundal Collier

•

14 May 07:15

OrganoClick: ABGSC Investor Days feedback - ABG

Strong momentum in GC&MP, headwinds in NW&FT and FW '25e-'27e sales CAGR of +14% New product launche...

OrganoClick

Analys | ABG Sundal Collier

•

14 May 07:14

CTT Systems: ABGSC Investor Days feedback - ABG

CTT Systems

Analys | ABG Sundal Collier

•

14 May 07:13

Green Landscaping Group: ABGSC Investor Days feedback - ABG

Expect continued M&A, mainly in DACH 5% adj. EBITA CAGR '24-'27e, M&A to support 10% growth 10-7x EB...

Green Landscaping

Analys | ABG Sundal Collier

•

14 May 07:12

Bredband2: Feedback from ABGSC's Investor Days - ABG

Scibase Q1’25: Continued US momentum - Redeye

Scibase is steadily executing on its long-term strategy, with the US and Germany continuing to drive...

Scibase

Analys | Analyst Group

•

13 May 14:21

Analyst Group kommenterar EcoRubs Q1-rapport

EcoRub

Analys | Analysguiden

•

13 May 13:48

EQL Pharma: Stark rapport med stabila utsikter framåt - Analysguiden

EQL Pharma presterar starkt och visar upp en väl tilltagen omsättningstillväxt i kombination med god...

Biovica: Collaboration with Tempus AI - Redeye

Vibrosense Dynamics: Rapportkommentar Q3'24/25 - Kalqyl

VibroSense redovisade en nettoomsättning om 0,75 MSEK (0,47) i kvartalet, vilket var en ökning med 5...

Biovica: Adding DiviTum market reach - Redeye

Hansa Biopharma: The new CEO expands the team - Redeye

The new CEO, Renee Aguiar-Lucander, has signed Maria Törnsén as COO and president of the US operatio...

Hansa Biopharma

Föregående Nästa